CompletedPhase 2NCT01562977
Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Andrés López Hernández, MDHospital Vall d´Hebrón
- Intervention
- Rituximab, Gemcitabine, Oxaliplatin, Dexametasone(drug)
- Enrollment
- 82 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2011 – 2015
Study locations (28)
- Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
- Hospital Duran i Reynals, Sabadell, Barcelona, Spain
- Hospital SAS de Jerez, Jerez de la Frontera, Cádiz, Spain
- Hospital Dr. Jose Molina Orosa, Arrecife, Lanzarote, Spain
- Fundación Hospital de Alcorcón, Alcorcón, Madrid, Spain
- Hospital Puerta de Hierro de Majadahonda, Majadahonda, Madrid, Spain
- Hospital Virgen de Arrixaca, El Palmar, Murcia, Spain
- Complejo Hospitalario de A Coruña, A Coruña, Spain
- Hospital Santa Creu i Sant Pau, Barcelona, Spain
- Hospital Vall d´Hebrón, Barcelona, Spain
- Hospital 12 Octubre, Madrid, Spain
- Hospital Gregorio Marañón, Madrid, Spain
- Hospital La Paz, Madrid, Spain
- Hospital Ramón y Cajal, Madrid, Spain
- Hospital Morales Meseguer, Murcia, Spain
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01562977 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic